9月14日，药明康德（02359）盘中上涨3.12%，报194.7港元，成交额1.48亿港元。消息面上，CXO板块近期持续走强，同行业康龙化成涨5.23%、药明生物涨2.85%、金斯瑞生物科技涨2.35%，板块联动效应显著。
基本面方面，公司上半年主营收入288.97亿元，同比增长38.94%，在手订单664.3亿元、同比增长25.2%，全年持续经营收入指引上调至35%—39%。此前摩根士丹利上调目标价至220港元并维持增持评级，9月已有44家券商将其列为金股。此外，公司近期密集因可转债转股发行H股，并宣布提前赎回剩余约49.73亿元可转债，显示债券持有人对公司前景的积极预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.